Frontlight ResearchEarly access
Active, not recruitingNo phase
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Key facts
- Who runs it
- University of Wuerzburg
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people enrolled
- Started
- Sept 2005
- Expected to end
- Dec 2030
- Type of study
- Observational
- Record updated
- 7 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- patients with histological proven adrenocortical carcinoma
- healthy persons as control group
- Life expectancy > 6 months
Who cannot take part
- autoimmune diseases
- severe clinical condition
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
- Record updated
- 7 May 2026